Pricing Log in Create free account
Friday 6 November 2026 Export ZBH’s income statement to Excel — free account

Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.

Revenue
+3.07%
EPS
−13.5%
Free cash flow
+29.8%
Total debt
−7.50%

Quarter to September 2026, against a year earlier

105.28 1.57 −1.47%
Market cap
$20.4B
P/E
26.5×
Fwd P/E
18.9×
Dividend yield
0.91%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Zimmer Biomet Holdings, Inc. 10-Q filed Nov 5, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:06 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2025: 3 added · 5 removed · 28 modified; 7 with only figures updated

  1. Removed · Results for the Three and Six-Month Periods ended June 30, 2025

    In the three and six-month periods ended June 30, 2025, our net sales increased 7.0 percent and 4.0 percent when compared to the same prior year period. Net sales growth was driven by a combination of our Paragon 28 acquisition, market growth, new product introductions and commercial execution across the organization. Paragon 28 had a positive impact on our net sales of 2.6 percent and 1.4 percent in the three and six-month periods ended June 30, 2025, respectively. Additionally, our net sales experienced a positive effect of 1.6 percent and 0.1 percent from changes in foreign currency exchange rates in the three and six-month periods ended June 30, 2025, respectively.